Beta
Trial Radar KI
Eine Studie entspricht den Filterkriterien
Kartenansicht

Efficacy of a Rehabilitation Program With the Pediatric Exoskeleton ATLAS 2030 in Pediatric Patients With Cerebral Palsy 60 Pädiatrisch

Aktiv, nicht rekrutierend
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT05926635 ist eine beobachtungsstudie zur Untersuchung von Zerebralparese und hat den Status aktiv, nicht rekrutierend. Die Studie startete am 3. August 2023 und soll 60 Teilnehmer aufnehmen. Durchgeführt von MarsiBionics ist der Abschluss für 11. Mai 2025 geplant. Die Daten von ClinicalTrials.gov wurden zuletzt am 27. September 2024 aktualisiert.
Kurzbeschreibung
Cerebral Palsy (CP) is the first cause of motor disability in children worldwide. ATLAS 2030 is a robotic gait exoskeleton designed to rehabilitate children with motor disability. The objective of this study is to analyse the efficacy of a training program with ATLAS 2023 in chilren with CP.
Ausführliche Beschreibung
A sample of children with CP will be divided into 2 groups, the experimental group will receive 32 sesions withe the ATLAS 2030 exoskeleton, whereas the control group will continue to receive their regular conventional therapy. Assessments will be performed at the beginning and the end of the intervention, as well as after 6, 9 and 12 months of the end of the intervention for follow-up.
Offizieller Titel

Efficacy of a Rehabilitation Program With the Pediatric Exoskeleton ATLAS 2030 in Pediatric Patients With Cerebral Palsy

Erkrankungen
Zerebralparese
Weitere Studien-IDs
  • SERMAS
NCT-Nummer
Studienbeginn (tatsächlich)
2023-08-03
Zuletzt aktualisiert
2024-09-27
Studienende (vorauss.)
2025-05-11
Geplante Rekrutierung
60
Studientyp
Beobachtungsstudie
Status
Aktiv, nicht rekrutierend
Stichwörter
exoskeleton
cerebral palsy
gait
rehabilitation
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
Exoskeleton group
sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their of their routine rehabilitation
ATLAS 2030
sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their routine rehabilitation
Control group
The children included in the control group will continue receiving their usual conventional therapy
Nicht zutreffend
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Gross Motor Function Measure-88 (GMFM-88)
To measure changes in gross motor function in children with cerebral palsy using the Gross Motor Functional Measure-88. The minimum value is 0 and the maximum value is 100 .When the GMFM score is lower, the skill level is lower.
At the beginning and the end of the intervention (4 months), as well as after 6, 9 and 12 months (follow-up)
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Modified Ashworth Scale (MAS)
changes in spasticity measured by the Modified Ashworth Scale (MAS). The spasticity of each muscle group is measured with a scale scored from 0 to 4, where 0 means no spasticity and 4 means the joint is fixed and therefore, the highest level of spasticity
Through study completion, along 1 year
Pediatric Quality of Life Inventory (PedsQLTM)
Changes in self perceived quality of life measured by the Pediatric Quality of Life Inventory (PedsQLTM). Every item is measured on a scale from 0 (higher quality of life) to 4 (lower quality of life)
At the beginning and the end of the intervention (4 months), as well as after 6, 9 and 12 months (follow-up)
Changes in Gait Deviation Index (GDI)
Changes in Gait Deviation Index (GDI) measured with a tridimensional motion analysis system
At the beginning and the end of the intervention (4 months), as well as after 6, 9 and 12 months (follow-up)
Teilnahme-Assistent
Eignungskriterien

Zugelassene Altersgruppen
Kind
Mindestalter
3 Years
Zugelassene Geschlechter
Alle
  • Medical authorization for standing, gait training and weight bearing.
  • Informed consent signed by legal guardians.
  • Confirmed diagnosis of cerebral palsy GMFCS levels III or IV.
  • Proper family acceptance and commitment level.
  • Receiving a minimum of 2 hours of therapy/activities promoting physical activity.
  • Maximum user weight of 35 kg.
  • Hip width (between greater trochanteres) less than or equal to 35 cm.
  • Length of the thigh (distance from the greater trochanter to the lateral condyle of the tibia) from 24cm to 33cm.
  • Tibia leg length (distance from the lateral condyle of the tibia to the lateral malleolus) from 23cm to 32cm.
  • Shoe size 27-33 (EU)

  • More than 8 sessions of robotic therapy during a month in the previous year to the beginning of the study.
  • Intensive rehabilitation during the study.
  • Imposibility of the family to fulfill treatment calendar.
  • Spasticity equal to 4 on the Modified Ashworth Scale at the time of use of the device.
  • More than 20º of hip and/or knee flessum at the time of using the exoskeleton.
  • Necessity to walk with 10º of hip abduction.
  • Necessity to walk with more than 9º of ankle dorsiflexion or plantar flexion or impossibility to use an orthosis to reach 90º in the ankle joint.
  • Severe skin lesion on parts of the lower extremities that are in contact with the device.
  • Scheduled surgery (rachis, limbs) for the duration of the study or surgery performed (rachis, extremities) in the last 6 months.
  • History of fracture without trauma. History of bone fracture traumatic in lower extremities or pelvic girdle in the last 3 months.
  • Severe rigid orthopedic deformities of the spine and/or lower limbs.
  • Cognitive or conductual disorders that may lead to a lack of adherence to the attachment to the device.
  • Conditions that provoke exercise intolerance.
  • Conductual disorders that may interfere with the use of the device or their participation in the study, like impulsiveness or the inability to understand simple comands.
  • Allergy to any of the ATLAS materials: cotton, nylon, polyester, polyamide, polyethylene or propylene.
MarsiBionics logoMarsiBionics
Keine Kontaktdaten vorhanden
5 Studienstandorte in 1 Ländern
Hospital Universitario Gregorio Marañón, Madrid, 28007, Spain
Hospital Infantil Universitario Niño Jesús-Servicio de Rehabilitación, Madrid, 28009, Spain
Hospital Universitario Niño Jesús-Servicio de Neuro Ortopedia, Madrid, 28009, Spain
Hospital Universitario 12 de Octubre, Madrid, 28041, Spain
Hospital Universitario La Paz, Madrid, 28046, Spain